Assembly Biosciences, Inc. (ASMB) Stock

Assembly Biosciences, Inc., a pioneering clinical-stage biotechnology firm based in South San Francisco, California, specializes in the discovery and development of innovative therapeutic candidates aimed at combating hepatitis B virus (HBV) infection within the United States. Central to its pipeline is Vebicorvir, the company's leading product candidate that has successfully completed Phase 2 clinical trials for the treatment of chronic HBV infection.

In addition to Vebicorvir, Assembly Biosciences is advancing ABI-H3733, which has completed Phase 1a clinical studies, and ABI-4334, currently undergoing pre-clinical trials, both targeted at addressing the complexities of HBV treatment. The company has established pivotal collaboration agreements with industry leaders such as BeiGene, Ltd., Arbutus Biopharma Corporation, and Antios Therapeutics, Inc. These partnerships aim to evaluate a triple combination therapy for chronic hepatitis B virus infection, underscoring Assembly Biosciences' commitment to advancing therapeutic solutions.

Founded in 2005 and formerly known as Ventrus Biosciences, Inc., the company rebranded as Assembly Biosciences, Inc. in June 2014. Assembly Biosciences also maintains strategic license agreements with Indiana University Research and Technology Corporation and Door Pharmaceuticals, LLC, further bolstering its robust research and development capabilities in the field of biotechnology. With a steadfast focus on innovation and scientific advancement, Assembly Biosciences continues to pioneer transformative treatments to address critical medical needs in the realm of infectious diseases.